GC
CGON icon

Guggenheim Capital’s CG Oncology CGON Stock Holding History

Guggenheim Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
+20,964
New +$1.37M 0.01% 846

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Guggenheim Capital's CGON Position: Q2 2026 in Review

Guggenheim Capital opened a new position in CG Oncology (CGON) in Q2 2026: 20,964 shares worth $1.49M. The stake represents 0.01% of the portfolio and ranks #846 among its holdings.

226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Guggenheim Capital held 20,964 shares of CG Oncology worth $1.49M as of Q2 2026.
  • CG Oncology was a new Guggenheim Capital position in Q2 2026.
  • CG Oncology made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #846 holding.
  • 226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.